Back to search results

NeoNOVA: Video AI for Neonatal Neurological Observation

This study, called NeoNOVA, is observing how well a non-contact video system, ArtemisAI Platform, can monitor babies' movements in the hospital. This system uses artificial intelligence (AI) to track a baby's body parts and movements. Researchers want to see if this AI can accurately identify these movements and if they relate to how doctors assess a baby's brain function (neurological exams). This could help doctors understand conditions like Neonatal Encephalopathy (brain injury in newborns) or Hypoxic-Ischemic Encephalopathy (brain damage from lack of oxygen). The study aims to enroll 200 infants. You can join if you are a parent or legal guardian willing to give consent and your baby is admitted to newborn services.

Study design
This is an observational study, meaning no specific treatments are given. It plans to include 200 infants and uses a single-arm design, where all participants receive the same observation.
What's involved
Your infant will have continuous bedside video monitoring from enrollment until they leave the hospital or withdraw from the study.
Compensation
Not stated in the trial record.
Follow-up
The primary goal of tracking AI accuracy is measured at study completion, an average of one week.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07628829

Neonatal Neurological Observation With Video AI

Recruiting
Not specifiedAll AgesObservational
Artemis AI Labs
~200 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:Continuous bedside video monitoring with AI anatomic landmark tracking for neurologic monitoring

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
AI Anatomic Landmark Tracking Accuracy
Measured over At study completion, an average of 1 week.

Conditions

Neonatal Encephalopathy
Hypoxic-Ischemic Encephalopathy
Sedation
Sleep

Explore related trials

Hypoxic Ischemic EncephalopathyNeonatal Encephalopathy

Where it's being run

2 sites across 1 states
New York2

Study leadership

  • Benjamin Glicksberg, PhD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Who to contact

Saum Naderi, MA
[email protected]
714-913-3641
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Signed and dated informed consent from at least one parent or legally authorized representative (LAR) who is at least 18 years old.
Parent/LAR expresses willingness to comply with study procedures for the duration of the infant's hospital stay.
Infant of any sex (including intersex/undetermined) admitted to newborn services (including the NICU) at a participating hospital.

Exclusion

Parents or LAR unable to provide informed consent or are under the age of 18.
Non-viable neonates

What this trial measures

  • AI Anatomic Landmark Tracking AccuracyAt study completion, an average of 1 week.

    The primary endpoint is analytical performance of the AI pose estimation system, quantified as median position error (in pixels) between AI-predicted and human-labeled anatomic landmark positions extracted from continuous bedside video. Success is defined as median position error less than typical human inter-rater variability.